MedTrace Logo

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

NCT04322890 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6000

Last updated 2024-10-22

No results posted yet for this study

Summary

The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

Conditions

  • Non Small Cell Lung Cancer
  • EGFR Gene Mutation
  • ALK Gene Mutation
  • ROS1 Gene Mutation
  • MET Gene Mutation

Interventions

DRUG

Osimertinib

Osimertinib 80mg, po, qd;

DRUG

Alectinib 150 MG

Alectinib 600mg, po, qd; Lorlatinib, 100mg, po, qd;

DRUG

Crizotinib 250 MG

Crizotinib 250 MG po bid.

DRUG

Savolitinib, Crizotinib.

Savolitinib, 300mg po qd.

DRUG

Chemotherapy

500mg, ivgtt, every 21day.

Sponsors & Collaborators

  • Hunan Province Tumor Hospital

    lead OTHER

Principal Investigators

  • Yongchang Zhang, MD · Hunan Cancer Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-16
Primary Completion
2026-12-24
Completion
2027-12-24

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04322890 on ClinicalTrials.gov